NYSE: BMYBristol Myers Squibb Co Stock
BMY Price
$60.13
Fair Value Price
N/A
Market Cap
$136.06B
52 Week Low
$46.40
52 Week High
$67.43
P/E
-214.75x
P/B
2.77x
P/S
3.82x
PEG
N/A
Dividend Yield
2.86%
Revenue
$34.86B
Earnings
-$563.00M
Gross Profit Margin
69.60%
Operating Margin
7.23%
Net Profit Margin
-1.60%
Debt to Equity
1.61
Operating Cash Flow
$13B
Beta
0.68
Next Earnings
Nov 5, 2020
Ex-Dividend
Oct 1, 2020
Next Dividend
Nov 2, 2020
Zen Score
High
Medium
Low
38
Industry average
Reasons for this score
BMY is good value based on its book value relative to its share price (2.77x), compared to the US market average (63.37x)
Valuation
BMY is good value based on its book value relative to its share price (2.77x), compared to the US Drug Manufacturers - General industry average (7.88x)
Valuation
BMY's Earnings (EBIT) of $2.52B can safely cover interest payments on company debt ($46.67B)
Financials
BMY News
Valuation
BMY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-214.75x
Industry
-10.98x
Market
46.79x
BMY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.77x
Industry
7.88x
Market
63.37x
BMY is good value based on its book value relative to its share price (2.77x), compared to the US market average (63.37x)
Valuation
BMY is good value based on its book value relative to its share price (2.77x), compared to the US Drug Manufacturers - General industry average (7.88x)
Valuation
BMY's financial health
Profit margin
Revenue
$10.8B
Net Income
-$775.0M
Profit Margin
-7.20%
BMY's Earnings (EBIT) of $2.52B can safely cover interest payments on company debt ($46.67B)
Financials
BMY's profit margin has decreased (-27.60%) in the last year from (26.00%) to (-1.60%)
Financials
Assets to liabilities
Assets
$129.3B
Liabilities
$79.3B
Debt to equity
0.94
BMY's short-term assets ($34.34B) exceed its short-term liabilities ($23.42B)
Financials
BMY's long-term liabilities ($55.50B) exceed its short-term assets ($34.34B)
Financials
BMY's debt has increased relative to shareholder equity (1.61), over the past 5 years ago (1.10)
Financials
BMY's debt to equity ratio (1.61) is considered high
Financials
Cash flow
Operating
$3.9B
Investing
$653.0M
Financing
-$1.1B
BMY's operating cash flow ($12.76B) is sufficient to service the company's debt ($46.67B)
Financials
Bristol Myers Squibb Stock FAQ
What is Bristol Myers Squibb's quote symbol?
(NYSE: BMY) Bristol Myers Squibb trades on the NYSE under the ticker symbol BMY. Bristol Myers Squibb stock quotes can also be displayed as NYSE: BMY.
How much is Bristol Myers Squibb's stock price per share?
(NYSE: BMY) Bristol Myers Squibb stock price per share is $60.13 today (as of Oct 23, 2020).
What is the 52 week high and low for Bristol Myers Squibb (NYSE: BMY)?
(NYSE: BMY) Bristol Myers Squibb's 52-week high was $67.43, and its 52-week low was $46.40. It is currently -10.83% from its 52-week high and 29.59% from its 52-week low.
What is Bristol Myers Squibb's Market Cap?
(NYSE: BMY) Bristol Myers Squibb's market cap is $136.06B, as of Oct 25, 2020.
Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.
Bristol Myers Squibb's market cap is calculated by multiplying BMY's current stock price of $60.13 by BMY's total outstanding shares of 2,262,689,755.
How much is Bristol Myers Squibb stock worth today?
(NYSE: BMY) Bristol Myers Squibb currently has 2,262,689,755 outstanding shares. With Bristol Myers Squibb stock trading at $60.13 per share, the total value of Bristol Myers Squibb stock (market capitalization) is $136.06B.
Bristol Myers Squibb stock was originally listed at a price of $47.32 in Dec 31, 1997. If you had invested in Bristol Myers Squibb stock at $47.32, your return over the last 22 years would have been 27.08%, for an annualized return of 1.10%.
©2020 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
